title: Long-term strict monitoring of plasma ghrelin and other serological markers of gastric diseases after Helicobacter pylori eradication.
abstract: We report on a case of chronic atrophic gastritis in which the serological markers of gastric diseases were strictly monitored for 2 years after successful Helicobacter pylori (H. pylori) eradication. A 31-year-old man with upper abdominal pain was diagnosed as having H. pylori infection. Laboratory examination revealed low serum levels of pepsinogen (PG) I, low PG I/II ratio, and low plasma levels of ghrelin. Upper gastrointestinal endoscopy revealed severe corpus-dominant atrophic gastritis. H. pylori eradication therapy was performed. Successful eradication was confirmed three months later by the 13C urea breath test. Decreased serum PG II levels and an increased serum PG I/II ratio were detected a week after completion of the eradication therapy. The serum anti-H. pylori IgG titer decreased to less than 75% of the baseline level by 24 weeks after completion of the eradication therapy. On the other hand, the plasma levels of total and active ghrelin showed no marked changes after successful eradication therapy. This is the first report of long-term follow-up of changes of the plasma ghrelin levels after H. pylori eradication therapy, the observations suggesting that reduction of plasma ghrelin levels cannot be achieved merely by H. pylori eradication, without resolution of the gastric atrophy.
authors.affiliation: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: Tatsuhiro
authors.initials: T
authors.lastname: Masaoka
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Imaeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hosoda
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ohara
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Morishita
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Ishii
authors.forename: Kenji
authors.initials: K
authors.lastname: Kangawa
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Hibi
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D005757:Gastritis, Atrophic / Q000097:blood* / Q000382:microbiology* / Q000473:pathology; D054439:Ghrelin; D016481:Helicobacter Infections / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D020116:Pepsinogen A / Q000097:blood; D020115:Pepsinogen C / Q000097:blood; D036361:Peptide Hormones / Q000097:blood*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D054439:Ghrelin; D036361:Peptide Hormones; D020115:Pepsinogen C; D020116:Pepsinogen A